XBIO's Business Model
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.xeneticbio.com |
| CEO (Chief Executive Officer) | James F. Parslow |
| Number of Employees | |
| IPO date | June 30, 2016 |
XBIO Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 40 Speen Street |
| City | Framingham |
| State | MA |
| Phone | 781 778 7720 |
| Zip Code | 01701 |
| Other Identifiers | |
| CIK | 0001534525 |
| ISIN | US9840156023 |
| CUSIP | 984015503 |
| Open | 3.8325 |
| Previous Close | 3.94 |
| Volume | 30.61 Thou. |
| Average Volume | 64.34 Thou. |
| Day’s Range | 3.6939 – 3.89 |
| 52 Week Range | 2.2-5.268 |
| MA (50) | 3.05852 |
| MA (200) | 3.63192 |
| Market Cap | 5.71 Mil. |
| Shares Out. | 1.54 Mil. |
| Earnings Date | Aug 11, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
